Changes in Hong Kong stocks | Rebon Pharmaceutical-B (09637) rose by more than 11% in early trading, two major institutions, GIC and LAV, increased their holdings of AP301 on the same day and entered the NDA sprint stage

The Zhitong Finance App learned that Rebang Pharmaceutical-B (09637) rose by more than 11% in early trading. As of press release, it had risen 9.62% to HK$30.54, with a turnover of HK$4.201,000.

According to the news, on June 29, Libang Pharmaceutical received a simultaneous increase in shares of two important institutional shareholders. Among them, the Singapore Sovereign Fund (GIC) increased its holdings by 882,000 shares to a total amount of about HK$384.416 million, and the shareholding ratio increased to 7.09%. On the same day, Eli Lilly Asia Fund (LAV) increased its holdings by 450,000 shares, involving about HK$2.777,800, and the shareholding ratio increased to 7.20%. Together, the two institutions increased their holdings by more than 1.32 million shares and invested approximately HK$58.72 million, demonstrating recognition of the long-term value of Libang Pharmaceuticals.

China Investment Securities International said that the AP301, the core product of Rebang Pharmaceuticals, has entered the NDA sprint stage and is only a 12-24 month window until commercialization. Guoyuan International, on the other hand, pointed out that innovation in the CKD field has almost stagnated over the past few decades. With its iron-based technology platform and excellent phase III data, it is expected to fill major clinical unmet needs in this field if successfully approved by the NDA.